RA
PTLA

Rational Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Rational Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,150
Closed -$62K – 406
2017
Q3 		$62K Buy
+1,150
New +$67.5K 0.03% 284

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Rational Advisors's PTLA Position: Q4 2017 in Review

Rational Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 1,150 shares — an estimated $62K sold.

Rational Advisors first reported a position in PTLA in Q3 2017 and held it in 1 quarter. The position peaked at $62K in Q3 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

  • Rational Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Rational Advisors sold 1,150 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $62K.
  • Rational Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 1 quarter.
  • Rational Advisors's Portola Pharmaceuticals, Inc. position peaked at $62K in Q3 2017.
  • 215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on Rational Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.